Site is Being Upgraded

A probiotic-based therapy for Metastatic cancers: Probiotic Lactobacillus Rhamnosus decreases the expression of PPM22 and inhibits migration, invasion and metastasis of cancer cells via up-regulation of its target gene, 5/December/2017, 2.18 pm

A probiotic-based immune enhancement therapy: Probiotic Lactobacillus Brevis increases SOX2 expression, and promotes innate immunity against bacterial infection, via down-regulation of its target gene, 5/December/2018, 2.02 pm
December 5, 2018
Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancer and other metastatic cancers: A pharmaceutical mixture encompassing Olaparib, an FDA-approved poly (adenosine diphosphate-ribose) polymerase inhibitor, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as KIBRA, p57Kip2,   p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 5/December/2018, 2.29 pm
December 5, 2018
Show all

From Significance of the study to Public health relevance:

Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them will die; (ii) cancer deaths globally are expected to be doubled by 2030; (iii) most of the cancer patients die due to metastasis; (iv) cancer treatment causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) bio-molecules that drive metastatic process; and the the way to prevent their expression; (ii) a way to activate immune system to combat cancer (Cancer immunotherapy); (ii) a cheaper alternative to the existing expensive anticancer drugs; (ii) a side-effect-free natural product-based drug; (iii) increase the therapeutic index of anticancer drugs; and (iv) a way to effectively treat and prevent metastatic progression and relapse of advanced/drug-resistant cancers.


Research findings to Therapeutic opportunity: 

A number of studies suggest that Probiotic Lactobacillus Rhamnosus prevents tumor growth. However, the mechanism of action is far from clear. This study suggests that Probiotic Lactobacillus Rhamnosus, by increasing the expression of its target genes, it may decrease the expression of metastasis promoter PMP22 (fig. 1). Thereby, it may inhibit migration, invasion and metastasis of cancer cells. Thus, pharmacological formulations encompassing Probiotic Lactobacillus Rhamnosus, either alone or in combination with other anticancer drugs,” may be used to inhibit the progression of invasive tumors (Fig. 2).

Fig1. Mechanistic insights into how probiotic Lactobacillus Rhamnosus functions as an anti-metastasis agent

Figure 2. Probiotic Lactobacillus Rhamnosus functions as an anti-metastatic agent.


Details of the research findings

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $2

Undisclosed information: How Probiotic Lactobacillus Rhamnosus decreases the expression of metastasis promoter PMP22

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/


References

CitationBoominathan, L., A probiotic-based therapy for Metastatic cancers: Probiotic Lactobacillus Rhamnosus decreases the expression of PPM22 and inhibits migration, invasion and metastasis of cancer cells via up-regulation of its target gene, 5/December/2017, 2.17 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.